PMID- 22310628
OWN - NLM
STAT- MEDLINE
DCOM- 20120524
LR  - 20120207
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 44
IP  - 1
DP  - 2012 Jan
TI  - The clinical significance of human leukocyte antigen antibody development in 
      kidney transplantation.
PG  - 264-6
LID - 10.1016/j.transproceed.2011.11.037 [doi]
AB  - BACKGROUND: This retrospective study uses the LAT-M (One Lambda Inc., Calif) 
      screen assay to reexamine the impacts (a), of pretransplant human leukocyte 
      antigen (HLA) antibody on long-term graft survival; (b) posttransplant HLA 
      antibody on long-term graft survival and (c) immunosuppressive regimen on 
      posttransplant HLA antibody development. PATIENTS AND METHODS: Pretransplant sera 
      from 222 renal transplant recipients and posttransplant sera from 216 renal 
      transplant recipients were studied for the impact of HLA antibody on long-term 
      graft survival. RESULTS: Among the patients who did not display pretransplant HLA 
      antibodies, 85% enjoyed 5-year and 59% 10-year graft survival, whereas the 
      patients who tested positive were 83% and 83% (P = .5596). Among the patients who 
      did not show posttransplant HLA antibodies, 99% enjoyed 5-, 91% 10-, and 65% 
      15-year graft survival, whereas for the 44 patients who tested positive they were 
      59%, 44%, and 30%, respectively (P < .0001). Patients prescribed cyclosporine + 
      myfortic (odds ratio 0.17, P = .05) or FK + Cellcept (odds ratio 0.36, P = .04) 
      showed the lowest posttransplant HLA antibody development. CONCLUSION: Both 
      regimens improve graft survival.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Lee, P-C
AU  - Lee PC
AD  - Department of Surgery, National Chang-Kung University Medical College and 
      Hospital, 138, Sheng-Li Road Tainan 70144, Taiwan. pochang@mail.ncku.edu.tw
FAU - Chen, Y-L
AU  - Chen YL
FAU - Chou, T-C
AU  - Chou TC
FAU - Wang, W-M
AU  - Wang WM
FAU - Wang, J-D
AU  - Wang JD
FAU - Hung, C-J
AU  - Hung CJ
FAU - Chang, S-S
AU  - Chang SS
FAU - Lin, Y-J
AU  - Lin YJ
FAU - Chan, R-H
AU  - Chan RH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (HLA Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Graft Rejection/immunology/prevention & control
MH  - Graft Survival/drug effects
MH  - HLA Antigens/*immunology
MH  - *Histocompatibility
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Isoantibodies/*blood
MH  - Kidney Transplantation/*immunology
MH  - Odds Ratio
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Taiwan
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2012/02/09 06:00
MHDA- 2012/05/25 06:00
CRDT- 2012/02/08 06:00
PHST- 2012/02/08 06:00 [entrez]
PHST- 2012/02/09 06:00 [pubmed]
PHST- 2012/05/25 06:00 [medline]
AID - S0041-1345(11)01634-4 [pii]
AID - 10.1016/j.transproceed.2011.11.037 [doi]
PST - ppublish
SO  - Transplant Proc. 2012 Jan;44(1):264-6. doi: 10.1016/j.transproceed.2011.11.037.